At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ophthalmic Solution in Diabetic Corneal Alteration
In Brief
An observational study evaluating CX-HA and CS for Dry Eye Disease (DED). Completed, enrolled 20 participants across 1 site.
Detailed Summary
Data analyses and revision of the DED symptoms in diabetic subjects. A novel ophthalmic solution containing cross-linked ha (CX-HA) and Chondroitin sulphate (CS) has been made available on the market. Both molecules have been widely studied for their viscoelastic and hydrating properties. Nevertheless, the use of CS in ophthalmology has been limited since, routinely, the molecule is of animal origins. This new ophthalmic solution is the first on the market formulated with a CS of non-animal origin.
Study Details
Timeline
Interventions
Sterile Isotonic ophthalmic solution